Results 171 to 180 of about 20,261,647 (304)
HEPATITIS C : A SILENT EPIDEMIC [PDF]
The hepatitis C virus is a leading cause of liver disease, liver cancer, and liver transplants, placing a huge burden on patients, their families, caregivers, and the healthcare system.CS260526-APublication date from document properties.hepatitis-c-a ...
core
Arthritis &Rheumatology, EarlyView.Objective To evaluate the risk of intrahepatic cholestasis of pregnancy (ICP) in azathioprine (AZA)–exposed versus unexposed systemic lupus erythematosus (SLE) pregnancies within the multicenter prospective Lupus in Pregnancy (LEGACY) cohort. Methods LEGACY is conducted at Systemic Lupus International Collaborating Clinics in Canada, South Korea, Peru,
Reem Farhat +14 more
wiley +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Hepatitis C : expansion of testing recommendations, 2012
Hepatitis C is an unrecognized health crisis in the United States. This life-threatening infection affects an estimated 3.2 million Americans, most of whom are \ue2\u20ac\u153baby boomers\ue2\u20ac? (those born from 1945 through 1965).
core
Arthritis &Rheumatology, EarlyView.Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Hepatology, EarlyView., 2022 Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim +12 more
wiley +1 more source
Progress Towards Eliminating Hepatitis C as a Public Health Threat in Norway. [PDF]
J Viral HepatWhittaker R +4 more
europepmc +1 more source
Viral hepatitis surveillance United States, 2015 [PDF]
The Centers for Disease Control and Prevention\ue2\u20ac\u2122s (CDC) National Notifiable Diseases Surveillance System (NNDSS) (1) receives viral hepatitis case reports electronically each week from state and territorial health departments in the United ...
core
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Arthritis &Rheumatology, EarlyView.Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source